NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice on July 20, 2026, to resolve an investigation into consulting and service agreements regarding federal healthcare laws. The company agreed to pay $9,813,260 to resolve the matter, which was previously addressed via a $11.2 million reserve accrued as of March 31, 2026. The settlement does not constitute an admission of liability. NeoGenomics, Inc. is a healthcare company providing precision oncology diagnostics.
